SHORT RHHBY ( ROCHE), SHORT AMLN (AMYLIN)
July 21, 2008
Roche’s acquisition of DNA ( Genentech ) shows change of the company’s long practiced successful strategy by the new CEO. This indicates lack of confidence
Proven Track Record of Most Accurate Analysis
Proven Track Record
of Most Accurate Analysis
Roche’s acquisition of DNA ( Genentech ) shows change of the company’s long practiced successful strategy by the new CEO. This indicates lack of confidence
Traders still have not caught up to slowing growth at VMW. We believe that the earnings report tomorrow will make it obvious that VMW is
Wall street is underestimating the price pressures in flash memories and overestimating the demand. Further our proprietary indicators show that aggressive money is accumulating Sandisk.
The street seems to underestimate the production hitches WFR is likely to experience due to complexity of the production processes as it expands capacity. Further
Even after the carnage in NCC, the fellow bank KEY has held up remarkably well. Our proprietary indicators and analysis of the similarities in these
Hyper growth phase is over, but the market does not seem to recognize it yet. Short here and add on bounces www.thearorareport.com THE ARORA REPORT,
We have been watching GE to short due to its massive exposure to the financial sector, but did not push the trigger due to its
Recent trip to India indicates that investors are underestimating oil demand in Asia. As the reality is recognized, oil may spike higher than generally anticipated.